CN102085285B - Traditional Chinese medicine combined prescription for treating paraplegia and bone fracture sequelae - Google Patents
Traditional Chinese medicine combined prescription for treating paraplegia and bone fracture sequelae Download PDFInfo
- Publication number
- CN102085285B CN102085285B CN2011100214401A CN201110021440A CN102085285B CN 102085285 B CN102085285 B CN 102085285B CN 2011100214401 A CN2011100214401 A CN 2011100214401A CN 201110021440 A CN201110021440 A CN 201110021440A CN 102085285 B CN102085285 B CN 102085285B
- Authority
- CN
- China
- Prior art keywords
- gram
- grams
- radix
- compositions
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine combined compound for treating paraplegia and bone fracture sequelae, which comprises a compound 1, a compound 2, a compound 3 and a compound 4, wherein the compound 1 comprises the following raw medicines: musk, calcined pyrite, roasted nux vomica, saffron, roasted goshawk bone and resina draconis; the compound 2 comprises the following raw medicines: red ginseng, bighead atractylodes rhizome, angelica, elsholtzia, amomun fruit, dried orange peel, bupleurum, eucommia, teasel, achyranthes and pawpaw; the compound 3 comprises the following raw medicines: gentiana macrophylla, teasel, cassia twig, aconitum fischeri peichb, dangshen, angelica tail, boneset, spatholobus stem and myrrh; and the compound 4 comprises the following raw medicines: eupolyphaga, myrrh, mastic, safflower, peach kernel, rhubarb, roasted leech, roasted earthworm, centipede, roasted pangolin, notoginseng, Chinese yam and fleece-flower root. The traditional Chinese medicine combined compound for treating paraplegia and bone fracture sequelae, which is disclosed by the invention, can effectively overcome the influence ofmetals to the absorption of body nutrients and medicines in vivo by combined medication, so that the treatment effect of the medicines is ideal, and the disease can not recur easily after being cured.
Description
Technical field
The present invention relates to a kind of Chinese medicine for oral administration, is a kind of associating Chinese medicine for oral administration compositions that is used to treat paraplegia and bone injury sequela.
Background technology
At present, along with the development of society and increasing of motor vehicles, a large amount of traffic accidents and the work high above the ground of building industry, the excavation of underground mineral resources cause a large amount of personal wounded or disabled accidents.When treatment paraplegia and bone injury, fracture rehabilitates through the operative treatment major part, and still, owing to the use draw point that has in the operative treatment process, metallic plate, drift bolt etc. are fixing, these metals often influence the absorption of human body to nutrition and medicine in vivo.The medicine of some treatment paraplegia and bone injury sequelas can not overcome metal effectively in vivo to the above-mentioned influence of human body, thereby influences the effect of successive treatment, makes patient's postoperative can not get timely rehabilitation; The medicine that has is undesirable to the therapeutic effect of bone injury sequela, recurs after the healing that the patient who causes can not cure, have, and must not be compelled amputation to cause permanent disbility, causes lifelong misery for patient and family thereof.The oral medicine short time use that also has some to be used to treat paraplegia and bone injury sequela has certain effect, and uses curative effect not obvious for a long time.The medicine for external use price that also has is high, has increased patient's treatment cost greatly.
Summary of the invention
The objective of the invention is to overcome the deficiency of prior art; Providing a kind of can overcome metal effectively and influence the deficiency of human body to nutrition and drug absorption in vivo; Make the therapeutic effect of medicine desirable, cure the back and be difficult for recurrence, and good effect, treatment cost are low, a kind of Chinese medicine combined group compound of treating paraplegia and bone injury sequela of having no side effect.
The object of the invention can be realized through following technical scheme:
A kind of Chinese medicine combined group compound of treating paraplegia and bone injury sequela is made up of compositions one, compositions two, compositions three and four or four compositionss of compositions, and its combined group compound is specific as follows:
The crude drug of processing of compositions one is: Moschus 0.3-1.0 gram, Pyritum (calcined) 1-3 gram, Semen Strychni (processed) 0.3-1.0 gram, Stigma Croci 0.2-0.8 restrain, process Os Accipiter 0.2-0.8 gram and Sanguis Draxonis 0.5-1.5 gram; Its manufacture method is earlier above-mentioned raw materials medicine processing powder to be broken into 100-200 purpose fine powder and mix homogeneously, in the fine powder of mix homogeneously being incapsulated again;
The crude drug of processing of compositions two is: Radix Ginseng Rubra 10-20 gram, Rhizoma Atractylodis Macrocephalae 10-20 gram, Radix Angelicae Sinensis 12-25 gram, Herba Moslae 8-15 gram, Fructus Amomi 10-20 gram, Pericarpium Citri Reticulatae 8-15 gram, Radix Bupleuri 10-20 gram, Cortex Eucommiae 12-25 gram, Radix Dipsaci 15-25 gram, Radix Achyranthis Bidentatae 20-30 gram and Fructus Chaenomelis 20-30 gram;
The crude drug of processing of compositions three is: Radix Gentianae Macrophyllae 10-20 gram, Radix Dipsaci 20-30 gram, Ramulus Cinnamomi 20-30 gram, Rhizoma Typhonii 20-30 gram, Radix Codonopsis 25-35 gram, Radix Angelicae Sinensis 25-35 gram, Herba Lycopi 30-40 gram, Caulis Spatholobi 35-50 gram and Myrrha 10-20 gram;
The crude drug of processing of compositions four is: eupolyphaga 10-20 gram, Myrrha 10-20 gram, Olibanum 10-20 gram, Flos Carthami 15-20 gram, Semen Persicae 15-20 gram, Radix Et Rhizoma Rhei 10-20 gram, process Hirudo 8-15 gram, Pheretima (processed) 10-20 gram, Scolopendra 5-15 gram, Squama Manis (processed) 10-20 gram, Radix Notoginseng 5-15 gram, Rhizoma Dioscoreae 10-20 gram and Radix Polygoni Multiflori 5-15 gram; Its manufacture method is earlier above-mentioned raw materials medicine processing powder to be broken into 100-200 purpose fine powder and mix homogeneously, in the fine powder of mix homogeneously being incapsulated again.
The object of the invention can also be realized through following technical scheme:
Its concrete combined group compound of the present invention is following:
The crude drug of processing of compositions one is: Moschus 0.6 gram, Pyritum (calcined) 2 grams, Semen Strychni (processed) 0.5 gram, Stigma Croci 0.5 restrain, process Os Accipiter 0.5 gram and Sanguis Draxonis 1 gram;
The crude drug of processing of compositions two is: Radix Ginseng Rubra 15 grams, the Rhizoma Atractylodis Macrocephalae 15 grams, Radix Angelicae Sinensis 15 grams, Herba Moslae 10 grams, Fructus Amomi 15 grams, Pericarpium Citri Reticulatae 10 grams, Radix Bupleuri 15 grams, the Cortex Eucommiae 15 grams, Radix Dipsaci 20 grams, Radix Achyranthis Bidentatae 25 grams and Fructus Chaenomelis 25 grams;
The crude drug of processing of compositions three is: Radix Gentianae Macrophyllae 15 grams, Radix Dipsaci 25 grams, Ramulus Cinnamomi 25 grams, Rhizoma Typhonii 25 grams, Radix Codonopsis 30 grams, Radix Angelicae Sinensis 30 grams, Herba Lycopi's 35 grams, Caulis Spatholobi 40 grams and Myrrha 15 grams;
The crude drug of processing of compositions four is: eupolyphaga 15 gram, Myrrha 15 grams, Olibanum 15 grams, Flos Carthami 15 grams, Semen Persicae 15 grams, Radix Et Rhizoma Rhei 15 grams, process Hirudo 10 grams, Pheretima (processed) 15 grams, Scolopendra 10 grams, Squama Manis (processed) 15 grams, Radix Notoginseng 10 grams, Rhizoma Dioscoreae 15 grams and Radix Polygoni Multiflori 10 grams.
The present invention compared with prior art has drug combination, can overcome metal effectively in vivo to the inhalation effects of human body nutrition and medicine, make the therapeutic effect of medicine desirable, cure the back and be difficult for recurrence, and good effect, treatment cost is low, the advantage that has no side effect.
Method for using of the present invention:
1, adopt drug combination, the capsule 3-8 of the oral present composition one restrains (weight with the pure fine powder of packing in the capsule is calculated, and takes capsular quantity like this and can calculate according to the weight of the pure fine powder of packing in the capsule) earlier after the meal; Compositions two is the introduction medicine of compositions one, the good compositions two of decocting for oral use immediately after having taken compositions one.Every day Orally administered composition one with compositions two once, took continuously 3-5 days.
2, after taking 3-5 days compositionss one and compositions two continuously, cut out compositions one and compositions two, from cutting out the good compositions three of decocting for oral use next day of compositions one and compositions two.Take compositions three every day once, took continuously 10 days.Take compositions continuously after 3 10 days, cut out compositions three.
3, play oral meal compositions four capsule 10-20 gram every day (weight of the pure fine powder of packing into is calculated in capsule, takes capsular quantity like this and can calculate according to the weight of the pure fine powder of packing in the capsule) in the next day that cuts out compositions three; Every day Orally administered composition four once, took compositions continuously four or three months, accomplish a course of treatment of drug combination.
Annotate: in order to make further rehabilitation of patient and after treatment effect (look patient's concrete condition and decide), taking compositions continuously after four or three months, can continue to take compositions 43 to 12 months; Can also repeat the above-mentioned course of treatment.
Function of the present invention: blood circulation promoting and blood stasis dispelling; Soothing liver and strengthening spleen; Live through collateral dredging; Wear numbness and pass through marrow; Affixed through refreshing.
The present invention's warp 500 routine clinical trial certificates, its cure rate 65%, effective percentage 90%, without any side effects.
Enumerate the several allusion quotation row cases that adopt the present invention's treatment below:
1, China certain, woman, 65 years strangers, people from Yongnian County, Hebei province.1 year bone does not connect of postoperative connect because of traffic accident left side lower limb comminuted fracture in 2004.Adopted the present invention to treat the recovery from illness course of treatment in 2005, leg-training can be recovered fully.
2, shut out so-and-so, woman, 50 years strangers, people from Yongnian County, Hebei province.Bone was still discontinuous after three art treatments because of industrial injury left side lower limb three place's comminuted fracture in 2003.Adopted the present invention to treat three recoveries from illness course of treatment (reuse the present invention continuously and treat three courses of treatment) in 2005.
3, Zhang, man, 60 years strangers, people from Ningling County, Henan Province.Multi-treatment was invalid because of traffic accident causes paraplegia under the thoracic vertebra in 2000.Adopted the present invention to treat two courses of treatment (reuse the present invention continuously and treat two courses of treatment) life can take care of oneself (life can take care of oneself back do not continue treatment) in 2002 because of economic condition.
The specific embodiment
Through the mode of tabulation, enumerate 10 specific embodiments of each compositions in the combined group compound of the present invention below, the raw material among each embodiment all is directly to buy from market.Compositions one and four manufacture method all are: earlier the crude drug processing powder in the compositions is broken into 100-200 purpose fine powder and mix homogeneously, in the fine powder of mix homogeneously being incapsulated again.The unit of weight of raw material is gram among each embodiment.
The method for using of combined group compound all is:
1, adopt drug combination, the capsule 3-8 of the oral present composition one restrains (weight with the pure fine powder of packing in the capsule is calculated, and takes capsular quantity like this and can calculate according to the weight of the pure fine powder of packing in the capsule) earlier after the meal; Compositions two is the introduction medicine of compositions one, and is for oral use immediately with the good compositions two of decocting after having taken compositions one.Every day Orally administered composition one with compositions two once, took continuously 3-5 days.
2, after taking 3-5 days compositionss one and compositions two continuously, cut out compositions one and compositions two, from cutting out the good compositions three of decocting for oral use next day of compositions one and compositions two.Take compositions three every day once, took continuously 10 days.Take compositions continuously after 3 10 days, cut out compositions three.
3, play oral meal compositions four capsule 10-20 gram every day (weight of the pure fine powder of packing into is calculated in capsule, takes capsular quantity like this and can calculate according to the weight of the pure fine powder of packing in the capsule) in the next day that cuts out compositions three; Every day Orally administered composition four once, took compositions continuously four or three months, accomplish a course of treatment of drug combination.
Compositions one specific embodiment: (annotate: unit is gram)
Compositions two specific embodiments: (annotate: unit is gram)
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
| Radix Ginseng Rubra | 10 | 20 | 15 | 20 | 12 | 18 | 19 | 16 | 14 | 15 |
| The Rhizoma Atractylodis Macrocephalae | 20 | 10 | 20 | 15 | 10 | 15 | 20 | 10 | 20 | 15 |
| Radix Angelicae Sinensis | 25 | 12 | 18 | 22 | 15 | 25 | 12 | 20 | 15 | 15 |
| Herba Moslae | 8 | 15 | 10 | 9 | 14 | 8 | 12 | 15 | 8 | 10 |
| Fructus Amomi | 10 | 20 | 15 | 20 | 12 | 18 | 19 | 16 | 14 | 15 |
| Pericarpium Citri Reticulatae | 8 | 15 | 10 | 9 | 14 | 8 | 12 | 15 | 8 | 10 |
| Radix Bupleuri | 10 | 20 | 15 | 20 | 12 | 18 | 19 | 16 | 14 | 15 |
| The Cortex Eucommiae | 25 | 12 | 18 | 22 | 15 | 25 | 12 | 20 | 15 | 15 |
| Radix Dipsaci | 20 | 15 | 25 | 20 | 15 | 20 | 25 | 15 | 25 | 20 |
| Radix Achyranthis Bidentatae | 25 | 30 | 20 | 20 | 30 | 25 | 20 | 30 | 20 | 25 |
| Fructus Chaenomelis | 30 | 20 | 20 | 30 | 25 | 20 | 30 | 20 | 25 | 25 |
Compositions three specific embodiments: (annotate: unit is gram)
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
| Radix Gentianae Macrophyllae | 10 | 20 | 15 | 10 | 20 | 10 | 20 | 15 | 010 | 15 |
| Radix Dipsaci | 30 | 20 | 25 | 30 | 20 | 25 | 30 | 20 | 25 | 25 |
| Ramulus Cinnamomi | 20 | 30 | 20 | 25 | 30 | 20 | 25 | 30 | 20 | 25 |
| Rhizoma Typhonii | 20 | 30 | 20 | 25 | 30 | 20 | 25 | 30 | 20 | 25 |
| Radix Codonopsis | 25 | 35 | 30 | 25 | 35 | 30 | 25 | 35 | 30 | 30 |
| Radix Angelicae Sinensis | 1.5 | 0.5 | 1 | 1.2 | 0.8 | 0.6 | 1.3 | 1.1 | 0.5 | 30 |
| The Herba Lycopi | 40 | 30 | 35 | 40 | 30 | 35 | 40 | 30 | 35 | 35 |
| Caulis Spatholobi | 35 | 40 | 45 | 50 | 35 | 40 | 45 | 50 | 35 | 40 |
| Myrrha | 10 | 20 | 15 | 10 | 20 | 10 | 20 | 15 | 010 | 15 |
Compositions four specific embodiments: (annotate: unit is gram)
Claims (2)
1. a Chinese medicine combined group compound of treating paraplegia and bone injury sequela is made up of compositions one, compositions two, compositions three and four or four compositionss of compositions, it is characterized in that:
The crude drug of processing of compositions one is: Moschus 0.3-1.0 gram, Pyritum (calcined) 1-3 gram, Semen Strychni (processed) 0.3-1.0 gram, Stigma Croci 0.2-0.8 restrain, process Os Accipiter 0.2-0.8 gram and Sanguis Draxonis 0.5-1.5 gram; Its manufacture method is earlier above-mentioned raw materials medicine processing powder to be broken into 100-200 purpose fine powder and mix homogeneously, in the fine powder of mix homogeneously being incapsulated again;
The crude drug of processing of compositions two is: Radix Ginseng Rubra 10-20 gram, Rhizoma Atractylodis Macrocephalae 10-20 gram, Radix Angelicae Sinensis 12-25 gram, Herba Moslae 8-15 gram, Fructus Amomi 10-20 gram, Pericarpium Citri Reticulatae 8-15 gram, Radix Bupleuri 10-20 gram, Cortex Eucommiae 12-25 gram, Radix Dipsaci 15-25 gram, Radix Achyranthis Bidentatae 20-30 gram and Fructus Chaenomelis 20-30 gram;
The crude drug of processing of compositions three is: Radix Gentianae Macrophyllae 10-20 gram, Radix Dipsaci 20-30 gram, Ramulus Cinnamomi 20-30 gram, Rhizoma Typhonii 20-30 gram, Radix Codonopsis 25-35 gram, Radix Angelicae Sinensis 25-35 gram, Herba Lycopi 30-40 gram, Caulis Spatholobi 35-50 gram and Myrrha 10-20 gram;
The crude drug of processing of compositions four is: eupolyphaga 10-20 gram, Myrrha 10-20 gram, Olibanum 10-20 gram, Flos Carthami 15-20 gram, Semen Persicae 15-20 gram, Radix Et Rhizoma Rhei 10-20 gram, process Hirudo 8-15 gram, Pheretima (processed) 10-20 gram, Scolopendra 5-15 gram, Squama Manis (processed) 10-20 gram, Radix Notoginseng 5-15 gram, Rhizoma Dioscoreae 10-20 gram and Radix Polygoni Multiflori 5-15 gram; Its manufacture method is earlier above-mentioned raw materials medicine processing powder to be broken into 100-200 purpose fine powder and mix homogeneously, in the fine powder of mix homogeneously being incapsulated again.
2. a kind of Chinese medicine combined group compound of treating paraplegia and bone injury sequela according to claim 1 is characterized in that:
The crude drug of processing of compositions one is: Moschus 0.6 gram, Pyritum (calcined) 2 grams, Semen Strychni (processed) 0.5 gram, Stigma Croci 0.5 restrain, process Os Accipiter 0.5 gram and Sanguis Draxonis 1 gram;
The crude drug of processing of compositions two is: Radix Ginseng Rubra 15 grams, the Rhizoma Atractylodis Macrocephalae 15 grams, Radix Angelicae Sinensis 15 grams, Herba Moslae 10 grams, Fructus Amomi 15 grams, Pericarpium Citri Reticulatae 10 grams, Radix Bupleuri 15 grams, the Cortex Eucommiae 15 grams, Radix Dipsaci 20 grams, Radix Achyranthis Bidentatae 25 grams and Fructus Chaenomelis 25 grams;
The crude drug of processing of compositions three is: Radix Gentianae Macrophyllae 15 grams, Radix Dipsaci 25 grams, Ramulus Cinnamomi 25 grams, Rhizoma Typhonii 25 grams, Radix Codonopsis 30 grams, Radix Angelicae Sinensis 30 grams, Herba Lycopi's 35 grams, Caulis Spatholobi 40 grams and Myrrha 15 grams;
The crude drug of processing of compositions four is: eupolyphaga 15 gram, Myrrha 15 grams, Olibanum 15 grams, Flos Carthami 15 grams, Semen Persicae 15 grams, Radix Et Rhizoma Rhei 15 grams, process Hirudo 10 grams, Pheretima (processed) 15 grams, Scolopendra 10 grams, Squama Manis (processed) 15 grams, Radix Notoginseng 10 grams, Rhizoma Dioscoreae 15 grams and Radix Polygoni Multiflori 10 grams.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100214401A CN102085285B (en) | 2011-01-11 | 2011-01-11 | Traditional Chinese medicine combined prescription for treating paraplegia and bone fracture sequelae |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100214401A CN102085285B (en) | 2011-01-11 | 2011-01-11 | Traditional Chinese medicine combined prescription for treating paraplegia and bone fracture sequelae |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102085285A CN102085285A (en) | 2011-06-08 |
| CN102085285B true CN102085285B (en) | 2012-01-11 |
Family
ID=44097446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100214401A Expired - Fee Related CN102085285B (en) | 2011-01-11 | 2011-01-11 | Traditional Chinese medicine combined prescription for treating paraplegia and bone fracture sequelae |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102085285B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526288A (en) * | 2011-11-12 | 2012-07-04 | 李承平 | Chinese patent medicine for treating traumatic injury |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1333025A (en) * | 2000-07-11 | 2002-01-30 | 李鹏 | Medicine for treating bone injury |
-
2011
- 2011-01-11 CN CN2011100214401A patent/CN102085285B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102085285A (en) | 2011-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101366892A (en) | Chinese medicinal composition for treating menorrhalgia | |
| CN103655989A (en) | Traditional Chinese medicine for external use for treating rheumatic arthritis | |
| CN102085285B (en) | Traditional Chinese medicine combined prescription for treating paraplegia and bone fracture sequelae | |
| CN1320433A (en) | Process for preparing powdered medicine to treat rhinitis and nasosinusitis | |
| CN101239159B (en) | Chinese medicinal composition for treating rheumatoild disease and preparation thereof | |
| CN105343433A (en) | Traditional Chinese medicine composition capable of promoting ovulation | |
| CN105434896A (en) | Traditional Chinese medicine for treating facial paralysis | |
| CN102038751A (en) | Traditional Chinese medicine formulation for treating infantile diarrhea | |
| CN1943635B (en) | Chinese traditional medicinal preparation for treating bone injuries and osteonosus | |
| CN102552627B (en) | Medicament for treating bone fracture, delayed union and nonunion | |
| CN102526514A (en) | Medicine used for treating allergic purpura | |
| CN1242806C (en) | Medicine | |
| CN105998331A (en) | Formula for treating sprains and contusions | |
| CN1695645A (en) | Medicament for treating leprous psora | |
| CN101239140A (en) | Chinese medicine for treating psoriasis | |
| CN104383097A (en) | Traditional Chinese medicine for treating lupus erythematosus | |
| CN103566264B (en) | A kind of Chinese medicine composition for the treatment of rheumatic arthritis | |
| CN102038825A (en) | Formula of traditional Chinese medicine for treating hyperthyroidism | |
| CN102309546A (en) | Production method of capsule for treating rhinitis and nasosinusitis | |
| CN103070992B (en) | Medicine for treating high myopia macular hemorrhages | |
| CN108888736B (en) | External-use bone reunion medicine and preparation method thereof | |
| CN1055845C (en) | Dieda Huoxuesan powder for curing fracture and injury | |
| CN1234402C (en) | Bone fracture therapeutic pharmaceuticals | |
| CN101897923A (en) | Chinese medicinal powder for treating nighttime lumbago | |
| CN1459310A (en) | Medicine for treating osteoproliferation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120111 Termination date: 20210111 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |